CD80 and CD86: CD28/CTLA-4 Costimulatory Signaling in Immune Research

Table of Contents

• What Are CD80 and CD86?
• CD80 Versus CD86
• CD28-Mediated Costimulation
• CTLA-4-Mediated Immune Regulation
• Trans-Endocytosis of CD80 and CD86
• Expression on Antigen-Presenting Cells
• CD80/CD86 in Cancer and Immunotherapy Research
• Assays for CD80/CD86 Biology
• Selecting Recombinant CD80 and CD86

What Are CD80 and CD86?

CD80, also known as B7-1, and CD86, also known as B7-2, are related cell-surface costimulatory ligands expressed mainly by professional antigen-presenting cells.

Both interact with CD28 and CTLA-4.

That simple statement hides a complex regulatory system.

CD28 is generally associated with positive costimulation, whereas CTLA-4 acts as a major negative regulator of T-cell activation.

CD80 and CD86 therefore sit at the center of a molecular competition that determines whether antigen recognition is supported by strong costimulation or restrained by inhibitory pathways.

These two molecules are among the most widely studied immunological CD antigens.

CD80 Versus CD86

Although CD80 and CD86 share receptors, they are not biologically identical.

Characteristic	CD80	CD86
Alternative name	B7-1	B7-2
Main receptors	CD28, CTLA-4	CD28, CTLA-4
Expression pattern	Often later or activation-associated	Often more rapidly inducible
Structural behavior	Can form dimers in some contexts	Primarily monomeric
Research role	Costimulation and CTLA-4 biology	Early costimulation and CTLA-4 biology

Their expression kinetics differ among APC types and activation conditions.

Therefore, a study that measures only CD80 may miss early costimulatory changes dominated by CD86, while a study measuring only CD86 may miss later changes in CD80.

CD28-Mediated Costimulation

TCR recognition of peptide-MHC provides antigen specificity but is not always sufficient for full naïve T-cell activation.

CD28 provides a major costimulatory signal.

When CD28 binds CD80 or CD86, downstream signaling can support:

• IL-2 production;
• proliferation;
• metabolic reprogramming;
• survival;
• differentiation.

This classical "signal 1 plus signal 2" framework remains valuable, although modern immunology recognizes that T-cell fate is shaped by many additional costimulatory and inhibitory receptors.

Fig 1. CD28 Costimulation by CD80 and CD86

CTLA-4-Mediated Immune Regulation

CTLA-4 is a homolog of CD28 but has a fundamentally different immunological role.

It binds CD80 and CD86 and can limit the availability of these ligands for CD28.

CTLA-4 is induced after conventional T-cell activation and is constitutively important in regulatory T cells.

The balance can be conceptualized as:

CD28 + CD80/CD86 → supports activation

CTLA-4 + CD80/CD86 → limits costimulation

However, CTLA-4 biology extends beyond simple competition.

Trans-Endocytosis of CD80 and CD86

A landmark study demonstrated that CTLA-4 can physically capture CD80 and CD86 from opposing antigen-presenting cells.

The ligand-receptor complex is internalized into the CTLA-4-expressing cell, reducing the amount of costimulatory ligand available on the APC surface.

This mechanism is called trans-endocytosis.

It provides a powerful explanation for how CTLA-4-expressing regulatory cells can suppress costimulation in a cell-extrinsic manner.

Fig 2. CTLA-4-Mediated Trans-Endocytosis

Expression on Antigen-Presenting Cells

Dendritic cells, B cells and monocytes can express CD80 and CD86.

Expression generally increases in response to activation or maturation signals, but exact kinetics depend on:

• Toll-like receptor stimulation;
• cytokines;
• tissue environment;
• cell type;
• differentiation state.

Therefore, measuring CD80 and CD86 is useful for assessing APC activation but cannot alone define functional competence.

A mature dendritic cell may express strong CD80/CD86 yet still be influenced by inhibitory cytokines, metabolic constraints or other checkpoints.

CD80/CD86 in Cancer and Immunotherapy Research

The pathway is closely linked to cancer immunotherapy because CTLA-4-directed therapies modify a system in which CD80 and CD86 are essential ligands.

CD28 signaling can also be important for effective T-cell responses during checkpoint modulation.

In tumors, relevant variables include:

• abundance of antigen-presenting cells;
• CD80/CD86 expression;
• regulatory T-cell activity;
• CTLA-4 expression;
• localization within tumor versus draining lymph node.

CD80 and CD86 are additionally used experimentally to engineer artificial antigen-presenting cells or costimulatory surfaces.

These systems help researchers study receptor activation under controlled conditions.

Assays for CD80/CD86 Biology

Assay	Main Purpose
CD80-CD28 binding	Measure costimulatory receptor interaction
CD86-CD28 binding	Compare ligand-specific interaction
CD80-CTLA-4 binding	Characterize inhibitory receptor affinity
CD86-CTLA-4 binding	Compare receptor-ligand kinetics
Competition assay	Test blockade by antibodies or biologics
T-cell reporter assay	Measure functional signaling
APC/T-cell coculture	Evaluate integrated immune response

SPR and BLI can reveal kinetic differences between receptor-ligand pairs.

However, ligand valency and surface density can significantly alter apparent affinity.

Therefore, results obtained with an Fc-fusion dimer should not automatically be compared with a monomeric protein.

Fig 3. CD80/CD86 Experimental Workflow

Selecting Recombinant CD80 and CD86

Matched recombinant CD antigens are useful when directly comparing CD80 and CD86.

Researchers should ideally keep the following variables consistent:

• species;
• extracellular-domain boundaries;
• tag;
• expression system;
• immobilization format.

Fc-Tagged Proteins

Useful for capture assays and multivalent presentation.

Potential limitation: avidity.

His-Tagged Proteins

Useful for ELISA and many quantitative biochemical assays.

Avi-Tagged/Biotinylated Proteins

Useful for oriented streptavidin immobilization.

Mammalian Expression

Often preferred when extracellular glycosylation and native-like folding are important.

For translational work, human and animal orthologs of these CD antigen proteins can also support cross-species characterization.

What is the difference between CD80 and CD86?

Both are B7-family ligands that bind CD28 and CTLA-4, but they differ in expression kinetics, structural behavior and interaction properties. CD86 is often induced earlier after APC activation, whereas CD80 may become more prominent later. Their shared but non-identical biology makes simultaneous measurement more informative than evaluating either ligand alone.

References

• Sansom DM, Manzotti CN, Zheng Y. What's the Difference Between CD80 and CD86? Trends Immunol. 2003;24(6):314–319. doi:10.1016/S1471-4906(03)00111-X.
• Qureshi OS, Zheng Y, Nakamura K, et al. Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4. Science. 2011;332(6029):600–603. doi:10.1126/science.1202947.
• Slavik JM, Hutchcroft JE, Bierer BE. CD28/CTLA-4 and CD80/CD86 Families: Signaling and Function. Immunol Res. 1999;19(1):1–24. doi:10.1007/BF02786473.
• Walker LSK, Sansom DM. Confusing Signals: Recent Progress in CTLA-4 Biology. Trends Immunol. 2015;36(2):63–70. doi:10.1016/j.it.2014.12.001.